The Living Laboratory
In June 2020, the University of Glasgow was delighted to be awarded £38m by the UKRI Strength in Places Fund to create the Living Laboratory for Precision Medicine. Bring together local business, academia, NHS, City Council, Scottish Enterprise and Glasgow Science Centre who are committed to working in partnership to support the long term economic regeneration of Govan, Glasgow.
The Living Laboratory will seek to create an internationally significant Precision Medicine campus, integrated with the Queen Elizabeth University Hospital, Govan - the UK's largest hospital. The campus will be a focal point for research and development, open innovation and commercialisation - bringing consortium partners together to unlock substantial productivity growth opportunities through Precision Medicine.
With the vision of improving health care outcomes for patients, and significant cost savings for the NHS, the Living Laboratory will focus on the real world implementation of pharmacogenomics based medication management, a Scottish Transcriptome Archive Resource (STAR), advanced imaging for Precision Medicine, a Digital Health Innovation Laboratory and a Health Innovation Hub providing grow-on space for collaboration.
Ultimately, the University of Glasgow will deliver this ambitious vision with £38m funding from the Strength in Places Fund, £22m of support from industry partners and an additional investment of £27.5m from Glasgow City Region City Deal and Glasgow City Council.
The Living Laboratory partners are: BioClavis, Canon Medical Research Europe Ltd, Glasgow City Council, Glasgow Science Centre, iCAIRD Ltd, Kadans Science Partner UK Ltd, MR Coiltech Limited, NHS Greater Glasgow & Clyde, Precision Medicine Scotland, Scottish Enterprise and Thermo Fisher Scientific.
This site will be updated regularly as the Living Laboratory initiative launches and we introduce you to our team and exemplar projects.
Watch the Strength in Places launch video to learn more regarding the UKRI's Strength in Places initiative.